Physician
Aspirus Eagle River Hospital & Clinics, INC
Aspirus Eagle River Hospital & Clinics, INC was paid $3.72M by Medicaid between Jan 2018 and Dec 2024, across 65 billing codes. Its largest line is 99283, emergency room visit (moderate) — 24% of everything it billed.
33Billing provider infoASPIRUS EAGLE RIVER HOSPITAL & CLINICS, INC
EAGLE RIVER, WI 54521
EAGLE RIVER, WI 54521
33aNPI1346204385assigned 04/14/2006
33bProvider typeHospitalist Physician
28Total paid$3.72M
24GClaims55,171
24DCodes billed65
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Hospitalist Physician providers in Wisconsin
Rank by total paid#1 of 35
Median peer was paid$14K
This provider vs. median269×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official YANG, JERRY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 7,658 | $496K | |
| 2019 | 7,357 | $373K | |
| 2020 | 6,513 | $439K | |
| 2021 | 10,022 | $517K | |
| 2022 | 9,053 | $715K | |
| 2023 | 8,516 | $733K | |
| 2024incomplete | 6,052 | $448K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 24% | 3,909 | 3,278 | $883K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 3,043 | 2,559 | $711K |
| 96361 | Intravenous infusion, hydration; each additional hour | 18% | 1,863 | 1,184 | $666K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 13% | 2,505 | 2,014 | $476K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 11% | 1,802 | 1,554 | $394K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.3% | 407 | 342 | $122K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.4% | 3,329 | 1,095 | $88K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.9% | 220 | 187 | $73K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.7% | 373 | 259 | $65K |
| 80053 | Comprehensive metabolic panel | <1% | 4,895 | 3,729 | $32K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 239 | 220 | $24K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 124 | 88 | $20K |
53 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 4,409 | $20K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 831 | $16K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 157 | $15K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 661 | $14K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 297 | $12K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 661 | $9K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 339 | $9K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,828 | $8K |
| 99001 | <1% | 1,148 | $6K | |
| 84484 | <1% | 1,212 | $6K | |
| 83735 | <1% | 2,109 | $6K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 78 | $5K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 22 | $5K |
| 81001 | <1% | 2,651 | $5K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 220 | $5K |
| 85610 | <1% | 1,590 | $3K | |
| 83690 | <1% | 667 | $3K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 54 | $2K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 13 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 617 | $2K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,213 | $2K |
| 71045 | Radiologic examination, chest; single view | <1% | 847 | $2K |
| 85651 | <1% | 659 | $1K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 39 | $1K |
| 83605 | <1% | 223 | $972.96 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 87 | $940.74 |
| 85730 | <1% | 364 | $885.94 | |
| 80306 | <1% | 69 | $850.95 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 56 | $846.87 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 151 | $741.77 |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,286 | $718.24 |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,512 | $654.97 |
| 80061 | Lipid panel | <1% | 46 | $647.56 |
| 97162 | <1% | 13 | $631.64 | |
| 87040 | <1% | 156 | $602.87 | |
| 84145 | <1% | 67 | $543.08 | |
| 87070 | <1% | 51 | $423.02 | |
| 73630 | <1% | 17 | $304.60 | |
| 83880 | <1% | 15 | $204.09 | |
| 81003 | <1% | 137 | $176.14 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 30 | $160.14 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 13 | $135.72 |
| 81025 | <1% | 14 | $115.79 | |
| 87186 | <1% | 17 | $99.27 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,003 | $91.91 |
| 85027 | <1% | 13 | $66.90 | |
| 82550 | <1% | 13 | $60.70 | |
| 85379 | <1% | 13 | $42.61 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 441 | $30.93 |
| 85652 | <1% | 13 | $25.31 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 120 | $2.36 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 499 | $1.15 |
| A9270 | Non-covered item or service | 0% | 701 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialYANG, JERRY (SVP & CHIEF FINANCIAL OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.